

2018 Buprenorphine Treatment Guidelines Committee Meeting
Agenda
June 6th, 2018
1:30-4:30pm CST
Ground Floor Hearing Room, Andrew Jackson Building

- I. Welcome/Introductions/Announcements
 - A. Opening remarks by TDMHSAS Commissioner Marie Williams
 - B. Tutorial on Emergency Rulemaking Process

- II. SB2009/HB2002-Discussion & Recommendations re: Injectable Buprenorphine Mono Product

- III. SB777/HB717
 - A. Discussion & Recommendations re: Requirements of SB777/HB717 re: changes to the Buprenorphine Treatment Guidelines
 1. Initiating periodic prescriber-initiated and prescriber-led discussions with patients re: patient readiness to taper down or taper off opioids employed in treatment.
 - B. Discussion & Solicitation of Advisory Comments re: Requirements of SB777/HB717 re: changes to TDMHSAS Rule 0940-05-35 (Office-Based Opiate Treatment Facilities) in order to establish:
 1. Standards for determining what constitutes a high dose of a the opioid employed in treatment at a nonresidential office-based opiate treatment facility;
 2. Protocols for initiating or switching a patient at a nonresidential office-based treatment facility to a high dose of the opioids employed in treatment;
 3. Protocols for initiating periodic prescriber-initiated and prescriber-led discussions with patients re: patient readiness to taper down or taper off the opioids employed in treatment; and,
 4. Requirements for approval of dispensing of buprenorphine products at a nonresidential office-based opiate treatment facility, including, but not limited to:
 - a) *Reporting dispensing authority to licensing board;*

2018 Buprenorphine Treatment Guidelines Committee Meeting

Agenda

June 6th, 2018

1:30-4:30pm CST

Ground Floor Hearing Room, Andrew Jackson Building

b) Checking the CSMD prior to dispensing; and,

c) Reporting to the CSMD amounts dispensed to the extent permitted by 42 CFR part 2.

IV. SB2095/HB2510-FYI re: Buprenorphine Prescribing Authority Working Group

V. Adjourn